About Event
Welcome to the LNP Formulation & Process Development Summit
Following exciting updates from Verve Therapeutics' GalNAc-LNP for PCSK9 for HFpEF treatment, ReCode raising $200m for precision genetic medicines with a 5th lipid element, Myeloid Therapeutics using LNP for the first ever delivery of mRNA-encoded CARs directly to humans, Lilly and Entos Pharmaceutics $50m collaboration agreement of LNP in multiple neurologic indications, lipid nanoparticles continues to dominate the biopharmaceutical industry in 2023.
Moving beyond mRNA vaccines, LNP is now giving scientists the opportunity to reimagine medicine, delivering curative and transformative treatment to patients. Emulating on the overwhelming success of LNP Formulation & Process Development Summit, the 2nd annual meeting returned to Boston in April 2023 as the one and only dedicated platform, uniting 350+ trailblazers, pioneers and new entrants to turbocharge next generation of LNP development.
3 streams of carefully curated content covered:
In depth discussions divulging IP and regulatory compliance for LNP drug products
Maximizing LNP's flexibility and versatility for payloads beyond mRNA vaccines with RNA, DNA, gene therapy and gene editing possibilities
Lipid Chemistry & Discovery Track: Novel lipid discovery and particle engineering to customize LNP composition for next generation LNPs
Formulation & Process Development Track: Optimise your LNP development techniques for enhanced manufacturability and product quality, and overcoming stability issues of LNP-nucleic acid drug products
LNP CMC & Manufacturing Track: Elevating your process control, CQAs framework for CMC, GMP compliance for seamless scale-up and achieving GMP compliance
Track A - Early Lipid Discovery
Track B - LNP Formulation & Development
Track C - LNP Scale Up
& CMC
- Adopt HTP screening to find the right lipid for your drug substance
- Configure and customize your LNP to gain IP advantage
- Particle engineering to enable targeted delivery beyond extrahepatic cells
- Understand LNP-cell biology to enable better in vivo-FIH translation
This track is dedicated to Lipid Chemistry, Lipid Discovery, Particle Engineering, Lipid Characterization, Delivery and Bioinformatics experts.
- Improve formulation in conjunction with upstream and downstream process development, with payload in considerations
- Enhance manufacturability and address impurity, subvisible particle and excipient concerns
- Improve stability of LNP-drug product for better logistics and COGS
- Integrate and define analytical technologies for LNP measures
Join this track if you're working in LNP Formulation, Process Development, LNP Engineering, Drug Substance and Drug Product or LNP Analytical/ Bioanalytical areas.
- Achieve seamless scale-up and optimize yield
- Adopt new platform technologies to ensure process control, CQAs and CPPs for regulatory compliance (GMP)
- Increase collaboration with your CDMOs for tech transfer and validation
- Ensure product quality for smooth regulatory approval and launch in market
Topics specifically dedicated to LNP Supply, Raw Materials, Clinical Manufacturing, CMC, GMP and Commercial Manufacturing, MSAT, Process Control and Tech Transfer.
In collaboration with Biogen, NIBR, AstraZeneca, Sanofi, Lupagen, RVAC Medicines, the 2nd LNP Formulation & Process Development Summit was dedicated to sharing lessons learned to fast-track your pipeline to deliver promises to patients.
Don't miss the 2024 meeting and stay at the forefront of science, network with 350+ LNP experts to gain competitive advantage to exploit LNP potentials.
What did you miss in 2023?
3 Dedicated
Streams:
One-stop-shop to leave no stone unturned in the LNP. Lipid Chemistry & Discovery, Formulation & Process Development and LNP CMC & Manufacturing
9 Interactive
Workshops:
Get stuck into brainteaser sessions including: Polymer Nanoparticles, Reference Materials & Standards, and Novel Routes of Administration.
Exclusive insights
from leading companies:
Arbor Biotech, Akagera Medicines, ReCode Therapeutics, NIBR, Lupagen and many more.